Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial by Qin, Shukui, Prof, Ren, Zhenggang, Prof, Meng, Zhiqiang, Prof, Chen, Zhendong, Prof, Chai, Xiaoli, Prof, Xiong, Jianping, Prof, Bai, Yuxian, Prof, Yang, Lin, Prof, Zhu, Hong, MD, Fang, Weijia, Prof, Lin, Xiaoyan, Prof, Chen, Xiaoming, MD, Li, Enxiao, Prof, Wang, Linna, MD, Chen, Chunxia, MSc, Zou, Jianjun, MD

Get full text

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised,... by Huang, Jing, Prof, Xu, Jianming, Prof, Chen, Yun, MD, Zhuang, Wu, MD, Zhang, Yiping, Prof, Chen, Zhendong, Prof, Chen, Jia, Prof, Zhang, Helong, Prof, Niu, Zuoxing, Prof, Fan, Qingxia, Prof, Lin, Lizhu, Prof, Gu, Kangsheng, Prof, Liu, Ying, MD, Ba, Yi, Prof, Miao, Zhanhui, MD, Jiang, Xiaodong, MD, Zeng, Ming, Prof, Chen, Jianhua, Prof, Fu, Zhichao, MD, Gan, Lu, MD, Wang, Jun, Prof, Zhan, Xianbao, Prof, Liu, Tianshu, Prof, Li, Zhiping, Prof, Shen, Lin, Prof, Shu, Yongqian, Prof, Zhang, Tao, PhD, Yang, Qing, MD, Zou, Jianjun, MD

Get full text

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial by Zhang, Li, Prof, Huang, Yan, MD, Hong, Shaodong, MD, Yang, Yunpeng, MD, Yu, Gengsheng, MD, Jia, Jun, MD, Peng, Peijian, MD, Wu, Xuan, MD, Lin, Qing, Prof, Xi, Xuping, Prof, Peng, Jiewen, MD, Xu, Mingjun, MD, Chen, Dongping, Prof, Lu, Xiaojun, MD, Wang, Rensheng, MD, Cao, Xiaolong, MD, Chen, Xiaozhong, MD, Lin, Zhixiong, Prof, Xiong, Jianping, MD, Lin, Qin, MD, Xie, Conghua, MD, Li, Zhihua, MD, Pan, Jianji, Prof, Li, Jingao, MD, Wu, Shixiu, Prof, Lian, Yingni, MD, Yang, Quanlie, MD, Zhao, Chong, Prof

Get full text